1
|
Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, Soria A, Staumont-Sallé D, Doutre MS, Amsler E, Mansard C, Dezoteux F, Darrigade AS, Milpied B, Bernier C, Perrot JL, Raison-Peyron N, Paryl M, Droitcourt C, Demoly P, Grosjean J, Mura T, Du-Thanh A. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE 2023; 11:3752-3762.e2. [PMID: 37652349 DOI: 10.1016/j.jaip.2023.08.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 08/17/2023] [Accepted: 08/20/2023] [Indexed: 09/02/2023]
Abstract
BACKGROUND Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU). OBJECTIVE We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU. METHODS We conducted a retrospective multicenter study in 9 French tertiary referral hospitals. All patients diagnosed with either spontaneous (CSU) and/or inducible (CIndU) CU who received at least 1 injection of OMA between 2009 and 2021 were included. We analyzed OMA drug survival and investigated possible determinants using Kaplan-Meier curves and log-rank tests. RESULTS A total of 878 patients were included in this study; 48.8% had CSU, 10.1% CIndU, and 41.1% a combination of both. OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them. The main reason for discontinuing treatment was the achievement of a well-controlled disease in 50% of patients. Half of the patients were still being treated with OMA 2.4 years after the initiation of treatment. Drug survival was shorter in patients with CIndU and in those with an autoimmune background. In atopic patients, OMA was discontinued earlier in patients achieving a well-controlled disease. A longer OMA drug survival was observed in patients with a longer disease duration at initiation. CONCLUSION In French patients with CU, the drug survival of OMA appears to be longer than that observed in previous studies conducted elsewhere, highlighting discrepancies in prescription and reimbursement possibilities. Further studies are warranted to develop customized OMA treatment schemes based on individual patterns.
Collapse
Affiliation(s)
- Julie Litovsky
- Département de Dermatologie, C.H.U de Montpellier, Montpellier, France
| | - Florence Hacard
- Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Pierre Bénite, France
| | - Florence Tétart
- Centre Erik Satie-Allergologie, Rouen University Hospital, Rouen, France
| | - Isabelle Boccon-Gibod
- Service de Médecine Interne, Centre National de Référence des Angioedèmes, CHU de Grenoble, Échirolles, France
| | - Angèle Soria
- Service de Dermatologie et Allergologie, Hôpital Tenon AP-HP, Sorbonne Université, Paris, France
| | - Delphine Staumont-Sallé
- CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | | | - Emmanuelle Amsler
- Service de Dermatologie et Allergologie, Hôpital Tenon AP-HP, Sorbonne Université, Paris, France
| | - Catherine Mansard
- Service de Médecine Interne, Centre National de Référence des Angioedèmes, CHU de Grenoble, Échirolles, France
| | - Frédéric Dezoteux
- CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | | | | | - Claire Bernier
- Plateforme Transversale d'Allergologie, Hôtel-Dieu-CHU de Nantes, Nantes, France
| | - Jean-Luc Perrot
- Service Dermatologie-Allergologie-Oncologie, CHU Nord Saint-Étienne U1059 INSERM, Saint-Priest-en-Jarez, France
| | | | - Marie Paryl
- Laboratoire de Biostatistiques, Épidémiologie, Santé Publique et Innovation Médicale Bespim, CHU De Nîmes, Nîmes, France
| | - Catherine Droitcourt
- Service de Dermatologie, CHU Rennes, Rennes, France; Université Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France
| | - Pascal Demoly
- Department of Allergology, University Hospital of Montpellier, Montpellier, France; IDESP UA11 University Montpellier, Montpellier, France
| | - Julien Grosjean
- Département d'Informatique BioMédicale, CHU de Rouen & LIMICS, U1142, Sorbonne Université, Paris, France
| | - Thibault Mura
- Laboratoire de Biostatistiques, Épidémiologie, Santé Publique et Innovation Médicale Bespim, CHU De Nîmes, Nîmes, France
| | - Aurélie Du-Thanh
- Département de Dermatologie, C.H.U de Montpellier, Montpellier, France.
| |
Collapse
|
2
|
Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2015; 3:400-7. [PMID: 25680926 DOI: 10.1016/j.jaip.2014.12.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Revised: 12/19/2014] [Accepted: 12/23/2014] [Indexed: 11/25/2022]
Abstract
BACKGROUND Identifying clinical characteristics of patients with chronic urticaria (CU) responsive to medication may help guide clinicians select treatment. OBJECTIVE The objective of this study was to investigate patient characteristics and medication use associated with urticaria control. METHODS A retrospective longitudinal chart review of adult patients with CU was conducted at a multisite allergy practice. Inclusion criteria required at least 4 CU office visits to allow for pre- and posttreatment assessment. Control corresponding to medication(s) used was assessed each visit. Univariate analysis followed by multiple logistic regression was performed. RESULTS A total of 221 patients with CU were included; 140 (63%) achieved complete control. The average time to control was 1.4 ± 2.7 years, which required 1-3 classes of medications. Dermatographia odds ratio (OR) = 1.85 (95% CI 1.3-2.7) or other physical urticarias, OR = 1.51 (1-2.4) and neutrophilic infiltrates on skin biopsy were markers of poor control. Thyroid autoantibodies were associated with better control using an H1-antihistamine. Whereas 22% were controlled on a second-generation H1-receptor antagonist plus a leukotriene receptor antagonist (LTRA), an additional 33% were controlled when cyclosporine was added. Use of a first or second H1-antagonist or LTRA was associated with a 3.5-16.9 times higher odds of complete CU control in those with dermatographia. The odds of achieving control for other forms of physical urticaria was greatest when colchicine was added (aOR = 32.6 [12.7-83.2]). CONCLUSIONS Patient-specific CU characteristics associated with medication-disease control may be useful for selecting treatment regimens. A subset of CU patients remains poorly controlled that indicates an unmet need for novel therapeutic agents.
Collapse
Affiliation(s)
- Priyal Amin
- Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Linda Levin
- Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio
| | - Sarah J Holmes
- Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Jillian Picard
- Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Jonathan A Bernstein
- Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
| |
Collapse
|